Scalper1 News
Drugmaker Alkermes (ALKS) popped to a 15-year high Wednesday after the company reported positive midstage results for its schizophrenia drug. Alkermes’ candidate, ALKS-3831, is a combination of olanzapine — better known as Eli Lilly’s (LLY) Zyprexa — and a novel product called samidorphan, which Alkermes hoped would reduce olanzapine’s common side effect of weight gain. The study found that patients on ALKS-3831 gained 37% less weight than those Scalper1 News
Scalper1 News